Real-World lupus study reveals how new drug performs outside clinical trials

NCT ID NCT06626945

First seen Jun 06, 2026 · Last updated Jun 12, 2026 · Updated 2 times

Summary

This study looked at 152 adults with systemic lupus erythematosus (SLE) who started taking anifrolumab during its first year on the market in Spain. Researchers tracked their disease activity, flare-ups, and remission rates using standard medical records. The goal was to see how well the drug works in real-world settings, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Barcelona, Spain

  • Research Site

    Granada, Spain

  • Research Site

    Jaén, Spain

  • Research Site

    L'Hospitalet de Llobregat, Spain

  • Research Site

    León, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Málaga, Spain

  • Research Site

    Mérida, Spain

  • Research Site

    Móstoles, Spain

  • Research Site

    Murcia, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Toledo, Spain

  • Research Site

    Valladolid, Spain

Conditions

Explore the condition pages connected to this study.